找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪(fǎng)問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Lebensqualit?t im Alter; Generationenbeziehun Andreas Motel-Klingebiel (Dr.),Hans-Joachim Kondra Book 2002 Springer Fachmedien Wiesbaden 20

[復(fù)制鏈接]
31#
發(fā)表于 2025-3-26 23:03:00 | 只看該作者
32#
發(fā)表于 2025-3-27 03:23:41 | 只看該作者
r the use in parasitology (He?mánek and Prokopi? 1989). In this study we investigated the possibility of thymic preparations to influence the resistance to model parasite infections (2 helminthoses — cysticercosis and ascaridosis and 2 protozooses — coccidiosis and cryptosporidiosis) in intact and i
33#
發(fā)表于 2025-3-27 07:59:59 | 只看該作者
34#
發(fā)表于 2025-3-27 12:38:34 | 只看該作者
Betina Hollsteintoxic side effects (Schumann and others, 1989). Reduction of toxicity may be accomplished by encapsulation of MTPPE in liposomes, which are taken up preferably by the cells of the MPS. The question is whether liposome-encapsulated MTPPE (LE-MTPPE) retains its activity. LE-MTPPE has proven to be bene
35#
發(fā)表于 2025-3-27 16:16:28 | 只看該作者
Jan Marbachsing nodal regions that may not be irradiated with more conformal techniques. Traditional forms of radiation in particular pose challenges for combination trials with immunotherapy. This chapter explores these issues in more detail and provides insights as to how radiation therapy can be optimized t
36#
發(fā)表于 2025-3-27 18:04:11 | 只看該作者
Frank Lettke auditory complications can lead to speech recognition deficits and sensorineural hearing loss. Ocular toxicities are among the most common adverse events resulting from the use of these agents. The majority of ocular immune-related adverse events (irAEs) are mild, low-grade, non-sight threatening,
37#
發(fā)表于 2025-3-28 01:25:04 | 只看該作者
38#
發(fā)表于 2025-3-28 02:46:10 | 只看該作者
39#
發(fā)表于 2025-3-28 08:14:48 | 只看該作者
Heinz Blaumeiser,Thomas Klie development to predict response to immunotherapy and risk of toxicity. This book chapter is a comprehensive review of immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.
40#
發(fā)表于 2025-3-28 11:37:24 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 21:07
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
湖州市| 天柱县| 香港| 山东省| 喜德县| 邹平县| 綦江县| 临武县| 北宁市| 利川市| 田东县| 商南县| 施秉县| 凉城县| 满洲里市| 罗定市| 大新县| 大渡口区| 永兴县| 调兵山市| 永新县| 嘉峪关市| 梨树县| 纳雍县| 乌兰察布市| 东丰县| 治县。| 车致| 依安县| 昆明市| 依安县| 台安县| 桐柏县| 古浪县| 富蕴县| 循化| 吉林市| 黔西| 潼南县| 郸城县| 四川省|